Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited is refocusing its efforts to enhance the value of its DEP® assets and advance dendrimer technology, following a strategic review led by new CEO Cheryl Maley. The company aims to accelerate the development and commercialization of its DEP® candidates, having treated over 350 patients in clinical programs, and is looking to strengthen partnerships to optimize shareholder returns. Starpharma’s forward-looking strategy includes a highly focused partnering of DEP® clinical assets to maximize their commercial potential.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
